Importing a Medical Device Into Saudi Arabia Without an MDMA: The Exceptions, and How Hospitals Use Them

The rule in Saudi Arabia is simple: a medical device needs a Medical Device Marketing Authorization (MDMA) before it can be imported and used. Manufacturers hear this and assume there is no way to get a product in front of a Saudi clinician until registration is complete, which can mean a year of waiting. That is not quite right. SFDA's importation requirements define a small number of exceptions under which a device without an MDMA can be cleared, each for a specific purpose, each with strict conditions. Understanding them lets a manufacturer and a hospital work together lawfully while registration runs in parallel. Misunderstanding them is how products get held at the port.

1. The principle: exceptions are for a purpose, never for the market

Every exception in MDS-REQ 5 shares the same logic. The device is imported for a defined, non-commercial purpose; the applicant is an establishment or person registered with SFDA (through the GHAD system) or a licensed importer; the shipment is licensed in advance; the licence is time-limited; and the device is used only for that purpose, then re-exported or destroyed where the rule requires it. None of these routes permits general sale, stocking, or promotion. An unregistered device brought in under an exception and then sold to another hospital is an illegal shipment, whatever the paperwork said.

2. The five routes that matter to manufacturers and hospitals

A sixth route, personal use by an individual for a home-use device, exists but is not relevant to institutional supply.

3. The humanitarian route: what people usually mean by "direct clearance"

When a Saudi hospital talks about obtaining a device "directly" for a patient before it is registered, the route in the requirements is Section 8, humanitarian purposes. Its conditions are specific:

• The device must be custom-made, or not available in the Kingdom for the treatment of the patient concerned.
• It is requested by, and under the responsibility of, a healthcare professional. The practitioner signs a Declaration and Attestation (Annex 3 of the requirements) stating the diagnosis and the justification, the reasons for selecting an unregistered device over registered alternatives, a risk–benefit assessment, and a comparison with conventional therapies, and accepting obligations on safety information, reporting, and patient disclosure.
• One application per patient. The route is not a mechanism for bringing in a quantity of product for general departmental use.
• Patient-specific and adaptable devices are excluded and require an MDMA. Custom-made devices must be labelled "custom-made" in Arabic and English.
• The importation licence is valid for three months.

The required documents are the importer's declaration (Annex 2), the purchase invoice, the bill of lading and certificate of origin where applicable, the practitioner's declaration (Annex 3), and, for custom-made devices, the practitioner's written prescription.

Two practical consequences follow. First, the initiative rests with the clinician and the institution, not the manufacturer: a manufacturer cannot "apply for direct clearance" of its own product. Second, the justification is medical, not commercial. A device that is simply better, cheaper, or newer than a registered alternative does not qualify; a device needed for a patient for whom no registered alternative is available or suitable can.

4. Research, education, and demonstration: the routes that support evaluation

For a manufacturer seeking to build clinical familiarity before registration, the research and education route and the demonstration route are often more useful than the humanitarian one.

Research and education (Section 5) allows a healthcare provider, educational facility, or research centre registered in GHAD, or a licensed importer or manufacturer, to bring in devices for educational or research use only. The applicant signs a Declaration of Beneficiaries (Annex 4), and the devices must be labelled for educational or research use or be covered by a beneficiary purchase order. On completion they are re-exported or destroyed, with proof to SFDA.

Demonstration and exhibitions (Section 6) allows devices to be imported for demonstration, labelled "For Demo Only" and "Not for sale", with a licence valid for six months and re-export or destruction within that period. The requirements are explicit that advertising a device without an MDMA is prohibited and that only specialised persons may be informed about it: a demonstration to clinicians is permitted; a marketing campaign is not.

Clinical studies (Section 4) require SFDA's prior approval of the trial itself. This is the route for generating Saudi clinical data, and it carries the obligations of any regulated study.

5. What these routes are not

• Not a substitute for registration. Every licence is temporary and purpose-bound. The MDMA remains the only route to sale, stocking, and tender participation.
• Not a volume channel. One patient per application under the humanitarian route; defined beneficiaries and quantities under the others.
• Not a promotional tool. Advertising an unregistered device is prohibited; informing specialists in a demonstration setting is the limit.
• Not open to unlicensed parties. Applicants must be licensed importers or establishments registered in GHAD; the ordinary shipment-clearance requirements on invoices, customs declarations, and shelf life still apply.

6. How this fits a market-entry strategy

Used properly, the exceptions let a manufacturer and its Saudi partner run clinical engagement and registration in parallel rather than in sequence. A typical sequence is: the Authorized Representative files the MDMA; the licensed partner supports a reference institution's research or demonstration import so that clinicians can evaluate the device; where a patient genuinely needs it and no registered alternative exists, the treating physician may use the humanitarian route under their own responsibility; and by the time the MDMA issues, the institution already knows the product and the partner is ready with vendor registration and, where relevant, a tender strategy.

The failure mode is equally typical: a manufacturer or distributor treats a research or demonstration import as an early sale, stocks units, and finds the shipment held, the licence revoked, and the registration file under a cloud. The exceptions reward manufacturers who respect their limits.

Frequently asked questions

Can a manufacturer apply for these routes directly?

No. Applications are made by licensed importers or by establishments and professionals registered with SFDA. The manufacturer supports the application through its Saudi partner.

Can a hospital keep stock of an unregistered device under the humanitarian route?

No. The route is one application per patient, with a three-month licence.

Does an import under an exception help the MDMA application?

Not formally. Registration is assessed on the technical file. Clinical familiarity in the Kingdom helps commercially once the MDMA is issued, and Saudi clinical data from an approved study can support the file.

What if a registered alternative exists?

Under the humanitarian route the practitioner must justify selecting an unregistered device over registered alternatives; under the national emergency route, an MDMA-approved alternative excludes the exception unless justified.

Related reading: SFDA Registration (MDMA) · Beyond NUPCO: How Saudi Arabia's Institutional Buyers Actually Purchase

Source: SFDA, Requirements on Importation and Shipments Clearance of Medical Devices, MDS-REQ 5, version 6.0, 19 July 2023. This article summarises published requirements for general guidance and is not regulatory advice for a specific shipment; confirm current requirements with SFDA or your Authorized Representative.